Record-setting presence at ASH reflects widespread recognition of clonoSEQ as a standard-of-care tool for personalizing patient care and accelerating drug developmentSEATTLE, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced that its next-generation sequencing (NGS)-based clonoSEQ® test for measurable r ...